GLP-1s and Birth Control: Check the Exact Medicine

The useful question is which medicine you take and how your contraception is administered. Tirzepatide, sold as Zepbound and Mounjaro, has a specific US label precaution for oral hormonal contraceptives. The reviewed semaglutide labels have different interaction findings.^{1, 2, 3, 4, 5} Foundayo has a separate 30-day precaution.⁶ A general warning that “GLP-1s affect the pill” loses that distinction.

This guide compares approved US prescribing information checked October 25, 2026. It can help you prepare a conversation with your prescriber or pharmacist; it does not choose contraception, change a prescription or calculate your chance of pregnancy. Tell the clinician your exact medication, formulation and birth-control method before starting treatment or increasing a dose.

Tirzepatide: four weeks after starting and each dose increase

Zepbound and Mounjaro labeling advises people using oral hormonal contraceptives to switch to a nonoral contraceptive method or add a barrier method for four weeks after starting tirzepatide and four weeks after every dose escalation. The same interaction sections say hormonal contraceptives administered by nonoral routes should not be affected.^{1, 2}

Keep both triggers in view. This is more than a precaution for the first month alone. For someone whose prescriber increases the dose, another four-week window follows that increase. This explanation is not a dosing timetable: the prescribing practice decides whether and when an increase is appropriate.

Ask the clinician or pharmacist how the instruction applies to your current method and upcoming treatment dates. Do not abandon a contraceptive prescription without an agreed alternative. The label gives a choice between a nonoral method and adding a barrier; it does not establish that one particular method is right for every reader.

Foundayo uses a different 30-day precaution

Foundayo (orforglipron) is an oral GLP-1 medicine, with its own label. It advises oral hormonal contraceptive users to switch to a nonoral method or add a barrier method for 30 days after starting and 30 days after each dose escalation. It says nonoral hormonal contraceptives should not be affected.⁶

Do not round its 30 days down to tirzepatide’s four weeks. Foundayo’s label also states that its effect on oral-contraceptive absorption has not been evaluated in a clinical trial. Its precaution is not evidence of an established contraceptive failure percentage. Bring the actual product name to the discussion; “a GLP-1 pill” does not identify the right instructions.⁶

The injection can affect an oral medicine

The tirzepatide labels connect this precaution to delayed stomach emptying, which can affect absorption of oral medicines. They describe the delay as greatest after the first dose and diminishing over time. That explanation does not cancel the repeated precaution after each increase.^{1, 2}

An injectable medicine can therefore raise a question about a swallowed contraceptive. The relevant distinction is the contraceptive's route, rather than whether both medicines are pills. Our semaglutide-versus-tirzepatide comparison covers other differences between the molecules; weight-loss averages cannot answer this interaction question.

Taking a contraceptive at a different time from the weekly injection is not a label-established replacement for the four-week precaution. Ask for a plan that addresses the actual instruction rather than assuming that a few hours of separation solves it.

Semaglutide has different findings, with limits

Ozempic injection labeling says evaluated oral medicines were not affected to a clinically relevant degree, while retaining caution about oral-drug use. Its interaction figure includes ethinylestradiol and levonorgestrel assessed at steady state, with no dose adjustment listed. The reviewed Wegovy and Rybelsus/oral Ozempic tablet labels also report no clinically significant pharmacokinetic differences for those hormones with semaglutide.^{3, 4, 5}

Those documents do not contain the same tirzepatide-specific four-week contraception instruction. That is a comparison of the labels, not a promise that contraception cannot fail. The findings do not cover every pill, missed dose, episode of illness or compounded preparation.

Name the exact product when seeking advice. The current Wegovy label covers injections and tablets; the Rybelsus document also covers Ozempic tablets, while Ozempic injection has its own label.^{3, 4, 5} Brand names alone can leave the route unclear. Our oral-versus-injectable guide explains why administration and formulation matter.

A semaglutide tablet adds a scheduling question

Wegovy tablets and Rybelsus/Ozempic tablets have their own administration instructions, including waiting at least 30 minutes afterward before taking other oral medicines, eating or drinking. These instructions are distinct from those for injections.^{3, 5}

If you also take an oral contraceptive, ask your pharmacist to review the complete schedule. A daily tablet routine and a weekly injection precaution answer different questions. Do not treat the semaglutide tablet interval as a universal birth-control rule, or as a way to avoid tirzepatide's separate precaution.

What the research measured

The tirzepatide label describes an interaction assessment involving a combined oral contraceptive containing 0.035 mg ethinyl estradiol and 0.25 mg norgestimate, together with a single 5 mg tirzepatide dose. It reports lower hormone exposure and delayed peak concentrations.^{1, 2} These are drug-concentration measurements, rather than a percentage of people whose contraception failed.

The semaglutide findings likewise concern evaluated medicines and pharmacokinetics.^{3, 4, 5} They should not become a made-up pregnancy-risk number. The label passages reviewed here do not establish an effectiveness trial for every contraceptive or identify all the participants behind each interaction assessment. Evidence about approved products also cannot validate compounded drops, tablets or other preparations as equivalent.

Illness, missed pills and pregnancy plans need another conversation

Vomiting, diarrhea or missed contraceptive doses raise pill-specific questions that this comparison cannot settle. Contact a pharmacist or contraception clinician promptly if you are concerned about protection, and use the instructions for your exact contraceptive. Do not improvise extra pill doses or an emergency-contraception schedule from a GLP-1 label.

Tell the prescribing practice promptly if pregnancy is suspected, recognized or being planned. For weight management, semaglutide labeling specifies stopping at least two months before planned pregnancy; make that plan with the clinician. Zepbound labeling calls for discontinuation when pregnancy is recognized, as does Wegovy labeling for weight management or cardiovascular risk reduction. Wegovy's liver-disease (MASH) indication and the diabetes labels have benefit-risk qualifications requiring clinical assessment.^{1, 2, 3, 4, 5} These differences are why this guide does not tell a reader to stop all diabetes treatment or select a replacement.

Bring your medication names, contraceptive route, last dose increase, any missed pills or illness, and pregnancy plans to that discussion. Ask who will answer before the next increase and how instructions will be recorded. Our provider-choice checklist includes access to care; our side-effects guide provides broader trial and label context. Neither can replace advice for your own medicines.